A hypothesis: Fructosamine-3-Kinase-Related-Protein (FN3KRP) catalyzes deglycation of Maillard intermediates directly downstream from fructosamines

Billy Bennett

Non-enzymatic glycation (a.k.a. Maillard reaction) is a series of random spontaneous reactions between reducing sugars and amines resulting in the formation of irreversible Advanced Glycation Endproducts (AGE’s). In food chemistry, this process is beneficial by contributing to flavor, aroma, texture and appearance of cooked foods. In vivo, however, Maillard reaction is deleterious because uncontrolled modification and crosslinking of biological macromolecules impairs their function. Consequently, chronic hyperglycemia of diabetes mellitus, for instance, leads to increased non-enzymatic glycation and diverse, multi-organ pathologies of diabetic complications. Based on the fact that toxic compounds, such as free radicals, are detoxified in vivo by specific defense mechanisms, one would expect to find mechanisms to control glucose toxicity as well.

Thus far only one such enzyme, Fructosamine-3-Kinase (FN3K), has been characterized. It operates intracellularly by catalyzing ATP-dependent removal of Maillard adducts, D-fructoselysines, from proteins thereby reducing the Maillard reaction flux from glucose to AGE’s When FN3K was isolated, a closely related but distinct protein copurified with it.

Unlike FN3K, however, this enzyme, Fructosamine-3-Kinase-Related Protein (FN3KRP), does not phosphorylate D-fructoselysines but it does phosphorylate several other (non-physiological) substrates. Interestingly, distribution of FN3KRP in nature appears to be nearly universal while that of FN3K is limited to endotherms. In this paper I suggest that the function of FN3KRP is deglycation of Maillard adducts downstream from fructoselysines. Such a mechanism, if proven correct, would be valuable given reports on apparent correlations between FN3KRP and some chronic conditions and/or diseases. Most recent such publication proposes that the FN3KRP gene may be a longevity gene.

Changes of Certain Metabolic and Cardiovascular Markers Fructosamine, H-FABP and Lipoprotein (a) in Patients with Hypothyroidism

Disorders of thyroid gland are common in general population, and it’s the most common affecting the endocrine system after diabetes mellitus. Thyroid function regulates a wide range of metabolic parameters, as well as affects some cardiovascular disease risk factors. Fructosamine is produced by a reaction between albumin (protein) and glucose; it is used to monitor patients with diabetes for short-term glycemic changes. H-FABP is present in the cytoplasm of cardiac myocytes, and delivers fatty acids into these cells. It has been shown to increase in myocardial injury. Lipoprotein LP(a) is consist of a special apolipoprotein called apoprotein (a), and it’s recognized as a cardiovascular disease independent risk factor.

To study whether certain metabolic and cardiovascular markers (fructosamine, H-FABP and lipoprotein (a) are changed in hypothyroid patients.

The current study included 280 overt hypothyroid, 272 with subclinical hypothyroidism compared with 270 healthy individuals of matched age and gender. For all subjects serum (TSH, T4, T3, FBS, HbA1c, fructosamine, triglycerides, cholesterol, lipoprotein (a), and Heart-type Fatty Acid-Binding Protein (H-FABP)) was measured.

Serum fructosamine level significantly elevated (p value <0.05) in patient with hypothyroidism when compared with control group, and no significant change between subclinical and control groups. There is no significant change in serum H-FABP between study subjects. There is significant increase in lipoprotein (a) in patient with hypothyroidism and those with subclinical group when compared with control group.

Serum fructosamine and level is significantly changed in patients with overt hypothyroidism when compared with euthyroid subjects. Also, we conclude that hypothyroidism increase risk of cardiovascular diseases by changing non-traditional marker such as lipoprotein (a), and no effect on H-FABP concentration.

A Potential Role for Fructosamine-3-Kinase in Cataract Treatment

Cataracts are the major cause of blindness worldwide, largely resulting from aging and diabetes mellitus. Advanced glycation end products (AGEs) have been identified as major contributors in cataract formation because they alter lens protein structure and stability and induce covalent cross-linking, aggregation, and insolubilization of lens crystallins. We investigated the potential of the deglycating enzyme fructosamine-3-kinase (FN3K) in the disruption of AGEs in cataractous lenses. Macroscopic changes of equine lenses were evaluated after ex vivo intravitreal FN3K injection.

The mechanical properties of an equine lens pair were evaluated after treatment with saline and FN3K. AGE-type autofluorescence (AF) was measured to assess the time-dependent effects of FN3K on glycolaldehyde-induced AGE-modified porcine lens fragments and to evaluate its actions on intact lenses after in vivo intravitreal FN3K injection of murine eyes. A potential immune response after injection was evaluated by analysis of IL-2, TNFα, and IFNγ using an ELISA kit. Dose- and time-dependent AF kinetics were analyzed on pooled human lens fragments. Furthermore, AF measurements and a time-lapse of macroscopic changes were performed on intact cataractous human eye lenses after incubation with an FN3K solution.

At last, AF measurements were performed on cataractous human eyes after crossover topical treatment with either saline- or FN3K-containing drops. While the lenses of the equine FN3K-treated eyes appeared to be clear, the saline-treated lenses had a yellowish-brown color. Following FN3K treatment, color restoration could be observed within 30 min. The extension rate of the equine FN3K-treated lens was more than twice the extension rate of the saline-treated lens. FN3K treatment induced significant time-dependent decreases in AGE-related AF values in the AGE-modified porcine lens fragments.

Furthermore, in vivo intravitreal FN3K injection of murine eyes significantly reduced AF values of the lenses. Treatment did not provoke a systemic immune response in mice. AF kinetics of FN3K-treated cataractous human lens suspensions revealed dose- and time-dependent decreases. Incubation of cataractous human eye lenses with FN3K resulted in a macroscopic lighter color of the cortex and a decrease in AF values. At last, crossover topical treatment of intact human eyes revealed a decrease in AF values during FN3K treatment, while showing no notable changes with saline. Our study suggests, for the first time, a potential additional role of FN3K as an alternative treatment for AGE-related cataracts.

Fructosamine is a valuable marker for glycemic control and predicting adverse outcomes following total hip arthroplasty: a prospective multi-institutional investigation

Recently, fructosamine has shown promising results in predicting adverse outcomes following total knee arthroplasty. The purpose of this study was to assess the utility of fructosamine to predict adverse outcomes following total hip arthroplasty (THA). A prospective multi-center study involving four institutions was conducted. All primary THA were evaluated for glycemic control using fructosamine levels prior to surgery. Adverse outcomes were assessed at a minimum 1 year from surgery. Primary outcome of interest was periprosthetic joint infection (PJI) based on the International Consensus Meeting (ICM) criteria. Secondary outcomes assessed were superficial infections, readmissions and death. Based on previous studies on the subject, fructosamine levels above 293 µmol/L were used to define inadequate glycemic control.

Rat Fructosamine,FTA ELISA kit
YLA0741RA-48T	Shanghai YL Biotech	48T	465 EUR
Rat Fructosamine,FTA ELISA kit
YLA0741RA-96T	Shanghai YL Biotech	96T	600 EUR
Fructosamine (FTA) ELISA Kit
abx573676-96tests	Abbexa	96 tests	801.6 EUR
Human Fructosamine,FTA ELISA kit
YLA1455HU-48T	Shanghai YL Biotech	48T	435 EUR
Human Fructosamine,FTA ELISA kit
YLA1455HU-96T	Shanghai YL Biotech	96T	562.5 EUR
Mouse Fructosamine,FTA ELISA kit
YLA1517MO-48T	Shanghai YL Biotech	48T	465 EUR
Mouse Fructosamine,FTA ELISA kit
YLA1517MO-96T	Shanghai YL Biotech	96T	600 EUR
General Fructosamine, FTA ELISA KIT
ELI-06964Ge	Lifescience Market	96 Tests	1063.2 EUR
General FTA/ Fructosamine ELISA Kit
E0093Ge	Sunlong	1 Kit	860.4 EUR
Rat Fructosamine ELISA kit
ELA-E2169r	Lifescience Market	96 Tests	1063.2 EUR
Rat Fructosamine, FA ELISA Kit
CELI-66009r	Lifescience Market	96 Tests	1063.2 EUR
Fructosamine ELISA Kit (OKEH02616)
OKEH02616	Aviva Systems Biology	96 Wells	934.8 EUR
Human Fructosamine, FA ELISA Kit
CELI-66009h	Lifescience Market	96 Tests	988.8 EUR
Mouse Fructosamine, FA ELISA Kit
CELI-66009m	Lifescience Market	96 Tests	1038 EUR
Canine Fructosamine, FA ELISA Kit
CELI-66009d	Lifescience Market	96 Tests	1113.6 EUR
Rabbit Fructosamine, FA ELISA Kit
CELI-66009Rb	Lifescience Market	96 Tests	1113.6 EUR
Bovine Fructosamine, FA ELISA Kit
CELI-66009b	Lifescience Market	96 Tests	1113.6 EUR
General Fructosamine, FA ELISA Kit
CELI-66009Ge	Lifescience Market	96 Tests	1063.2 EUR
Porcine Fructosamine, FA ELISA Kit
CELI-66009p	Lifescience Market	96 Tests	1113.6 EUR

Overall 1212 patients were enrolled in the present study and were available for follow-up at a minimum of 1 year from surgery. Of those, 54 patients (4.5%) had elevated fructosamine levels (> 293 µmol/L) and these patients were 6.7 times more likely to develop PJI compared to patients with fructosamine levels below 293 µmol/L (p = 0.002). Patients with elevated fructosamine were also associated with more readmissions (16.7% vs. 4.4%, p < 0.007) and a higher mortality rate (3.7% vs. 0.6%, p = 0.057).

These associations remained statistically significant in a multi-regression analysis after adjusting for age, comorbidities and length of stay; Adjusted odds ratio were 6.37 (95% confidence interval 1.98-20.49, p = 0.002) for PJI and 2.68 (95% confidence interval 1.14-6.29, p = 0.023) for readmissions. Fructosamine is a good predictor of adverse outcomes in patients undergoing THA and should be used routinely to mitigate morbidity and mortality risk.